| Adial Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Co.'s lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. We show 4 historical shares outstanding datapoints in our ADIL shares outstanding history coverage, used to compute ADIL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADIL market cap history over the course of time is important for investors
interested in comparing ADIL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADIL versus a peer is one thing; comparing
ADIL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADIL can fluctuate over the course of history.
With this page we aim to empower investors researching ADIL by allowing them to research the ADIL market cap history.